D iltiazem hydrochloride is a calcium channel blocker that exhibits frequency-dependent effects at the atrioventricular (AV) node such that it markedly slows AV nodal conduction and prolongs AV nodal refractoriness when conduction through the AV node is rapid, e.g., during atrial fibrillation or atrial flutter.' Diltiazem has been shown to be safe and effective in slowing a rapid ventricular rate in patients with atrial fibrillation or atrial flutter2-8 and converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.9"10 A few studies have examined the pharmacokinetics and pharmacodynamics of intravenous diltiazem. These studies have been conducted in healthy volunteers,11" 2 patients with hypertension (without significant cardiac or pulmonary disease),13"4 and patients with a history of PSVT. 15 There have been no pharmacokinetic/pharmacodynamic studies of diltiazem in patients with atrial fibrillation or atrial flutter, who generally are older and have significant underlying cardiac and/or pulmonary disease. 16 The objective of this study was to characterize the pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter.
Methods

Patients
Thirty-two patients with established atrial fibrillation or atrial flutter (duration, >24 hours) were included in 8 (25) 6 (19) 14 (44) 6 (19) 5 (16) *One patient may have more than one diagnosis.
this pharmacokinetic and pharmacodynamic study (Table 1). On entry into the study, all patients had a ventricular rate (documented electrocardiographically) .120 beats per minute for at least 15 minutes before receiving study drug. Atrial fibrillation was diagnosed by the absence of discrete, regular atrial activity. Atrial flutter was diagnosed by the presence of discrete flutter waves typically noted in limb leads II, III, and aVF at a rate of 250-350 min'. None of the patients were hypotensive (systolic blood pressure, <90 mm Hg); in severe congestive heart failure (New York Heart Association functional class III or IV); had a history of sinus node dysfunction, second-or third-degree AV block, or Wolff-Parkinson-White syndrome; or had a known allergy to diltiazem. In 30 of 32 patients, no calcium channel blocker, class la or Ic antiarrhythmic agent (e.g., quinidine, procainamide, flecainide, or encainide), amiodarone, or /3-blocker had been administered for at least five elimination half-lives before administration of diltiazem. One patient received verapamil and one patient received propranolol within five elimination half-lives of entry into the study. Twenty-two of the 32 patients had received digoxin before entry into the study. Only two patients received digoxin during the study. One patient received one dose of 0.25 mg at hour 0.5 of the infusion, and one patient received one dose of 0.125 mg at hour 1.5 of the infusion. None of the other patients received digoxin during the bolus or infusion parts of the study. Mean+SD digoxin plasma concentrations before and after the study were 0.69±0.3 ng/ml (range, 0.2-1.2 ng/ml) and 0.63±0.23 ng/ml (range, 0.3-1.2 ng/ml) (therapeutic range, 0.9-2.1 ng/ml), respectively.
Study Design
The patients included in this study were part of a double-blind, randomized, placebo-controlled study. 17 Patients were enrolled at five participating study centers (see "Appendix") after the protocol was approved by the investigational review board at each center. The study design is illustrated in Figure 1 . Before entry into the study, each patient had signed an informed consent.
On entry into the study, a medical history was obtained, and a physical examination was performed. If the presence of a persistent atrial fibrillation or atrial flutter (ventricular rate >120 beats per minute for at least 15 minutes) was confirmed at baseline, the patient was given a 20-mg intravenous bolus dose of open-label diltiazem over 2 minutes (drug period 1). Patients who did not achieve a therapeutic response (defined as heart rate <100 beats per minute, >20% decrease in heart rate from baseline, or conversion to sinus rhythm) within 15 minutes of the 20-mg dose were given a 25-mg If response was not lost at the end of the 24 hours in drug periods 2 or 4, the infusion was stopped and patients were entered into a 10-hour washout period. Subsequent therapy for atrial fibrillation or atrial flutter was at the discretion of the patient's physician.
Heart rate and blood pressure were obtained before administration of intravenous diltiazem, immediately after the 2-minute injection of intravenous diltiazem, and every 5 minutes until response was achieved in the 17-minute observation period (drug periods 1 and 3). Blood (plasma) samples, blood pressure, and heart rate measurements were obtained at 1, 3, 5, 10, 15, 20, and 24 hours during the continuous double-blind and openlabel infusions (drug periods 2 and 4, respectively) and at 1, 3, 5, and 10 hours during the washout. Heart rate and rhythm were obtained from 1-minute ECG rhythm strips (lead II), and blood pressure was obtained from a standard sphygmomanometer.
Of the 32 patients included in the pharmacokinetic/ pharmacodynamic analysis, 31 patients (16 in drug period 2 and 15 in drug period 4) received a 24-hour infusion of intravenous diltiazem. One patient received a 16-hour infusion of intravenous diltiazem in drug period 4. Seventeen patients received the 10-mg/hr infusion only; in 15 other patients, the infusion of 10 mg/hr was increased to 15 mg/hr. Adequate washout data were obtained in all 32 patients. Five other patients who received a 24-hour intravenous infusion of diltiazem are not included in the pharmacokinetic/pharmacodynamic analysis because their plasma concentrations of diltiazem could not be obtained due to assay interference (four patients) and lost plasma samples (one patient).
Plasma Sample Collection, Assay, and Data Analysis Blood samples were drawn into plastic syringes and transferred to silanized glass tubes with 10 units/ml heparin. Plasma was separated by centrifugation and frozen at -20°C. Plasma diltiazem and primary metabolite-desacetyldiltiazem and N-desmethyldiltiazemconcentrations were determined by high-performance liquid chromatography with ultraviolet detection. The lower limits of quantitation for diltiazem, desacetyldiltiazem, and N-desmethyldiltiazem were 6.25, 3.12, and 3.12 ng/ml, respectively. Over a plasma concentration range of 6.25-200 ng/ml for diltiazem and 3.12-200 ng/ml for the metabolites, the daily reproducibility for the The relation between plasma diltiazem concentration and percent change in heart rate from baseline and between percent change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline were examined by fitting individual patient data to linear, loglinear, Em., and sigmoidal Em.. pharmacodynamic models20 using a least-squares nonlinear regression analysis.2' A strong pharmacodynamic relation was defined as r2>0.6 for individual patient data. The model of best-fit was identified by comparing Akaike and r2 values. The presence or absence of hysteresis was determined in each patient by examining the degree of overlap of the ascending and descending limbs of the percent heart rate reduction versus plasma diltiazem concentration plot. A two-sample t test was used to compare the pharmacokinetic and pharmacodynamic variables between the two different infusion rates of diltiazem and two types of arrhythmias (atrial fibrillation and atrial flutter). Statistical summary data are described as mean+±SD.
Results
Pharmacokinetics
Diltiazem. Plasma diltiazem concentration-time profiles for three patients are illustrated in Figure 2 . Pharmacokinetic parameters were obtained in 31 of 32 patients (one patient had insufficient plasma data to characterize AUC.) as summarized in representing a difference of 27%. For the majority of the pharmacokinetic parameters calculated, the intersubject variability was similar for both infusion rates. Metabolites. Pharmacokinetic parameters for the two principal plasma metabolites of diltiazem-desacetyldiltiazem and N-desmethyldiltiazem -following the 10-and 15-mg/hr infusions are summarized in Table 3 . The mean maximum plasma concentration for desacetyldiltiazem following the 10-and 15-mg/hr infusions were 30±14 and 68±25 ng/ml, respectively. N-Desmethyldiltiazem achieved slightly lower maximum plasma concentrations of 23±6 and 45±13 ng/ml after 10-and 15-mg/hr infusions, respectively. The times to reach maximum plasma concentration for desacetyldiltiazem were similar to diltiazem. The time to reach maximum plasma concentration for N-desmethyldiltiazem were slightly longer than times for diltiazem and desacetyl- (Table 4 ). All patients who responded to the bolus and infusion of diltiazem had a >20% decrease in heart rate from baseline. The majority of infusion responders also had a heart rate <100 beats per minute. None of the patients converted to sinus rhythm.
The time course profiles for plasma diltiazem concentration and percent heart rate reduction paralleled each other as illustrated for three patients in Figure 2 . Peak heart rate reduction was generally observed at the time of maximal plasma diltiazem concentration. When percent heart rate reduction was plotted as a function of plasma diltiazem concentration, hysteresis was not observed in 27 of 32 patients.
A strong pharmacodynamic relation (defined as r2>0.6 for model of best-fit) between plasma diltiazem concentration and percent reduction in heart rate was observed in 84% (27/32) of the patients. Percent heart rate reduction-plasma diltiazem concentration profiles with model-predicted line of best-fit are illustrated in Figure 3 for these same three patients. Data for one patient represent some of the best data to model, data for another patient represent the most difficult data to model, and data for a third patient represent a middle case. The relation between plasma diltiazem concentration and percent heart rate reduction for each of the 32 patients was described by a sigmoidal Em., pharmacodynamic model: percent heart rate reduction=Emax x (plasma diltiazem concentration)N' EC50N + (plasma diltiazem concentration)N, where Ema., is the maximal percent reduction in heart rate, EC50 is the plasma diltiazem concentration at half-maximal effect, and N is a sigmoidicity parameter. The estimated pharmacodynamic parameters from these models are summarized in Table 5 . The mean Ema,, was 52% with a mean ECQ0 of 110 ng/ml. The Emax and EC50 were not significantly different (p>0.05) for patients receiving the 10-and 0.78±0.2 (25.3) CV, coefficient of variation; E..X, maximum percent reduction in heart rate from baseline; EC0, plasma concentration that achieves one half the maximum percent reduction in heart rate from baseline; N, sigmoidicity parameter. patients were similar (52+17% versus 50+16%, respectively). The mean EC50 was higher for atrial flutter patients than for atrial fibrillation patients (160±117 versus 101+76 ng/ml, respectively); however, the difference was not statistically significant (p=0.15). As summarized in Table 6 , the model predicts that mean plasma diltiazem concentrations of 79, 172, and 294 ng/ml produce a 20%, 30%, and 40% reduction in heart rate, respectively.
A relation between plasma diltiazem concentration and percent reduction in SBP and DBP from baseline was not observed in the majority of patients (mean r2: SBP, 0.35+±0.24; DBP, 0.36+0.2). A strong relation (r2>0.6) between plasma diltiazem concentration and percent reduction in SBP and DBP was seen in only four and three patients, respectively. Mean baseline SBP of 132 mm Hg was reduced by 13% in response to the bolus and by 9% at hour 1 and hour 5, 8% at hour 10, and 7% at hour 20 and hour 24 of the infusion. Mean baseline DBP of 85 mm Hg was reduced by 12% in response to the bolus and by 12% at hour 1 and hour 5, 9% at hour 10, and 10% at hour 20 and hour 24 of the infusion (Table 4) .
Washout. After the 24-hour infusion, there was a gradual and steady return of leart rate and blood pressure toward baseline (Table 4) . Over the 10-hour washout period, mean percent reduction in heart rate from baseline ranged from 38% at washout hour 1 to 16% at washout hour 10. The mean percent reduction in SBP and DBP ranged from 7% and 10%, respectively, at washout hour 1 to 1% and 1%, respectively, at washout hour 10. During the 10-hour washout period, 13 patients maintained response, and eight other patients had received additional antiarrhythmic therapy.
Adverse Events There were no deaths, prolonged hospitalizations, permanent disabilities, or dosage reductions as a result of an adverse event. Of the 32 patients, five had adverse events that were related to diltiazem: Three experienced a transient injection site reaction, one experienced a warm sensation lasting 3 minutes, and one had asymptomatic ventricular pauses lasting as long as 4.2 seconds.
Discussion
The pharmacokinetics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter have not been previously reported. In this study, the mean maximum plasma concentration of diltiazem was 242 and 470 ng/ml following the 10-and 15-mg/hr infusions, respectively. The apparent elimination half-life of diltiazem was 6.9 hours. There was a nonlinear dose-dependent decrease in systemic clearance from 42 to 31 1/hr after the 10-and 15-mg/hr infusions of diltiazem, respectively. Steady-state conditions for diltiazem were not attained during the 24-hour infusion. The elimination half-life of 6.9 hours of diltiazem in these patients suggests steady-state conditions would be achieved after 32 hours of continuous infusion.
The disposition properties of intravenous diltiazem in patients with atrial fibrillation and atrial flutter differ from those in normal volunteers. In the study by Weir Characterization of the relation between plasma diltiazem concentration and heart rate reduction in atrial fibrillation and atrial flutter patients has not been previously reported. We were able to establish this relation in 27 of the 32 patients studied. These 27 patients demonstrated no hysteresis between a change in plasma diltiazem concentration and a corresponding change in heart rate, i.e., little or no delay in response after an adjustment in plasma diltiazem concentration. This finding is of clinical importance because it suggests that heart rate change in atrial fibrillation and atrial flutter patients may be affected fairly rapidly after increasing or decreasing the rate of a continuous infusion of diltiazem. By establishing a pharmacodynamic model in each patient, we were able to predict the therapeutic diltiazem plasma concentration required to produce a given percent reduction in heart rate. The mean therapeutic plasma diltiazem concentrations required to produce 20%, 30%, and 40% reductions in heart rate were 79, 172, and 294 ng/ml, respectively.
Five of the 32 patients studied had relatively poor model fits of the pharmacodynamic data. Each of these patients demonstrated clockwise hysteresis between a change in plasma diltiazemn concentration and a corresponding change in heart rate, which could suggest development of tolerance. An explanation for the resultant poor fits of the data in these five patients is not readily apparent and requires further investigation. Two patients had atrial flutter. Three patients had atrial fibrillation, one of whom did not maintain therapeutic response during the infusion.
Five patients in this study had atrial flutter. Atrial flutter patients had similar Em. (50% versus 52%) but fibrillation patients. Although the EC50 was not significantly different, possibly because of the small number of atrial flutter patients in the study, these findings suggest atrial flutter patients may require higher diltiazem plasma concentrations than atrial fibrillation patients to achieve the same magnitude of heart rate reduction. We did not observe a relation between plasma diltiazem concentration and percent reduction in blood pressure from baseline in the majority of our patients. The lack of a correlation may be a result of postprandial effects and diurnal variation on blood pressure. In addition, we cannot rule out a change in hemodynamics secondary to reduction of a rapid ventricular rate after administration of diltiazem.
Plasma concentrations of the principal metabolites desacetyldiltiazem and N-desmethyldiltiazem were low, i.e., <15% and <10% of the plasma concentration of diltiazem, respectively. The relative potencies of desacetyldiltiazem and N-desmethyldiltiazem compared with diltiazem (based on animal studies) ranged from 50% to 100% and from 20% to 30%, respectively (data on file at Marion Merrell Dow Inc.). Thus, in this study, the concentration of these metabolites of diltiazem is expected to contribute little to the pharmacodynamics in patients with atrial fibrillation and atrial flutter.
Conclusions
First, the pharmacokinetics of diltiazem in patients with atrial fibrillation and atrial flutter are nonlinear with an apparent dose-dependent decrease in systemic clearance with increasing infusion rate. Second, with a sigmoidal Em. model, there is a strong relation between diltiazem plasma concentration and percent heart rate reduction. Third, the plasma concentrations of the principal metabolites desacetyldiltiazem andN-desmethyldiltiazem are low and are not expected to contribute significantly to the pharmacodynamics of intravenous diltiazem in these patients. 
